A soluble form of CD4 (T4) protein inhibits AIDS virus infection - PubMed (original) (raw)

. 1988 Jan 7;331(6151):82-4.

doi: 10.1038/331082a0.

Affiliations

• PMID: 3257544
• DOI: 10.1038/331082a0

A soluble form of CD4 (T4) protein inhibits AIDS virus infection

K C Deen et al. Nature. 1988.

Abstract

CD4 (T4) is a glycoprotein of relative molecular mass 55,000 (Mr 55K) on the surface of T lymphocytes which is thought to interact with class II MHC (major histocompatibility complex) molecules, mediating efficient association of helper T cells with antigen-bearing targets. The CD4 protein is also the receptor for HIV, a T-lymphotropic RNA virus responsible for the human acquired immune deficiency syndrome (AIDS) (refs 4-7). To define the mechanisms of interaction of CD4 with the surface of antigen-presenting cells and with HIV, we have isolated the CD4 gene and expressed this gene in several different cellular environments. Here we describe an efficient expression system in which a recombinant, soluble form of CD4 (sCD4) is secreted into tissue culture supernatants. This sCD4 retains the structural and biological properties of CD4 on the cell surface, binds to the envelope glycoprotein (gp110) of HIV and inhibits the binding of virus to CD4+ lymphocytes, resulting in a striking inhibition of virus infectivity.

PubMed Disclaimer

Similar articles

• A soluble CD4 protein selectively inhibits HIV replication and syncytium formation.
  Hussey RE, Richardson NE, Kowalski M, Brown NR, Chang HC, Siliciano RF, Dorfman T, Walker B, Sodroski J, Reinherz EL. Hussey RE, et al. Nature. 1988 Jan 7;331(6151):78-81. doi: 10.1038/331078a0. Nature. 1988. PMID: 2829023
• Soluble CD4 molecules neutralize human immunodeficiency virus type 1.
  Traunecker A, Lüke W, Karjalainen K. Traunecker A, et al. Nature. 1988 Jan 7;331(6151):84-6. doi: 10.1038/331084a0. Nature. 1988. PMID: 2829024
• HIV infection is blocked in vitro by recombinant soluble CD4.
  Fisher RA, Bertonis JM, Meier W, Johnson VA, Costopoulos DS, Liu T, Tizard R, Walker BD, Hirsch MS, Schooley RT, et al. Fisher RA, et al. Nature. 1988 Jan 7;331(6151):76-8. doi: 10.1038/331076a0. Nature. 1988. PMID: 2829022
• The role of CD4 in HIV binding and entry.
  Sattentau QJ, Moore JP. Sattentau QJ, et al. Philos Trans R Soc Lond B Biol Sci. 1993 Oct 29;342(1299):59-66. doi: 10.1098/rstb.1993.0136. Philos Trans R Soc Lond B Biol Sci. 1993. PMID: 7904348 Review.
• Are blockers of gp120/CD4 interaction effective inhibitors of HIV-1 immunopathogenesis?
  Herbeuval JP, Shearer GM. Herbeuval JP, et al. AIDS Rev. 2006 Jan-Mar;8(1):3-8. AIDS Rev. 2006. PMID: 16736946 Review.

Cited by

• Profound structural conservation of chemically cross-linked HIV-1 envelope glycoprotein experimental vaccine antigens.
  Martin GM, Russell RA, Mundsperger P, Harris S, Jovanoska L, Trajano LF, Schiffner T, Fabian K, Tolazzi M, Scarlatti G, McFarlane L, Cheeseman H, Aldon Y, Schermer EE, Breemen M, Sliepen K, Katinger D, Kunert R, Sanders RW, Shattock R, Ward AB, Sattentau QJ. Martin GM, et al. NPJ Vaccines. 2023 Jul 13;8(1):101. doi: 10.1038/s41541-023-00696-w. NPJ Vaccines. 2023. PMID: 37443366 Free PMC article.
• Potential of antiviral peptide-based SARS-CoV-2 inactivators to combat COVID-19.
  Gurung AB, Ali MA, Lee J, El-Zaidy M, Aljowaie RM, Almutairi SM. Gurung AB, et al. PLoS One. 2022 Jun 3;17(6):e0268919. doi: 10.1371/journal.pone.0268919. eCollection 2022. PLoS One. 2022. PMID: 35657783 Free PMC article. Retracted.
• Past HIV-1 Medications and the Current Status of Combined Antiretroviral Therapy Options for HIV-1 Patients.
  Weichseldorfer M, Reitz M, Latinovic OS. Weichseldorfer M, et al. Pharmaceutics. 2021 Oct 27;13(11):1798. doi: 10.3390/pharmaceutics13111798. Pharmaceutics. 2021. PMID: 34834213 Free PMC article. Review.
• Distinct conformations of the HIV-1 V3 loop crown are targetable for broad neutralization.
  Friedrich N, Stiegeler E, Glögl M, Lemmin T, Hansen S, Kadelka C, Wu Y, Ernst P, Maliqi L, Foulkes C, Morin M, Eroglu M, Liechti T, Ivan B, Reinberg T, Schaefer JV, Karakus U, Ursprung S, Mann A, Rusert P, Kouyos RD, Robinson JA, Günthard HF, Plückthun A, Trkola A. Friedrich N, et al. Nat Commun. 2021 Nov 18;12(1):6705. doi: 10.1038/s41467-021-27075-0. Nat Commun. 2021. PMID: 34795280 Free PMC article.
• Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection.
  Wang X, Cao M, Wu Y, Xu W, Wang Q, Ying T, Lu L, Jiang S. Wang X, et al. Molecules. 2021 Mar 31;26(7):1964. doi: 10.3390/molecules26071964. Molecules. 2021. PMID: 33807292 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program